Jonathan Alfred Fletcher MD
Clinical Cytogenetics
Associate Professor of Pathology, Brigham and Women's Hospital
Join to View Full Profile
75 Francis St# BrighamBoston, MA 02115
Phone+1 617-732-7883
Dr. Fletcher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1986 - 1988
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1986- Boston University Medical CenterResidency, Internal Medicine, 1981 - 1985
Boston University School of MedicineClass of 1981
Certifications & Licensure
MA State Medical License 1985 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Medical Genetics and Genomics Clinical Cytogenetics
Publications & Presentations
PubMed
- 8 citationsE3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.Alfonso García-Valverde, Jordi Rosell, Sergi Sayols, David Gómez-Peregrina, Daniel F Pilco-Janeta
Oncogene. 2021-10-07 - 32 citationsE3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer.Ke Li, Xufen Zheng, Hua Tang, Yuan-Sheng Zang, Chunling Zeng
The Journal of Experimental Medicine. 2021-08-02 - 14 citationsYWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathwaysWen-Bin Ou, Meijun Z. Lundberg, Shuihao Zhu, Nacef Bahri, Anastasios Kyriazoglou
Oncogenesis. 2021-05-04
Journal Articles
- LMTK3 Is Essential for Oncogenic KIT Expression in KIT-Mutant GIST and MelanomaJonathan A Fletcher, William H Fleming, Nature
Press Mentions
Demetri’s Team Approach Translates into Success in Sarcoma ResearchFebruary 10th, 2016
Grant Support
- Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatmentUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2027
- Genetics and Genomics of Leiomyosarcoma (LMS): Improved understanding of cancer biology and new approaches to diagnosis and treatmentUNIVERSITY OF MICHIGAN AT ANN ARBOR2022–2027
- Core--Molecular CytogeneticsNational Cancer Institute2000–2002
- Translocation Of 8-13 In Stem-Cell Leukemia/LymphomaNational Cancer Institute1997–1999
- Tumor Suppressor Loci In MesotheliomaNational Cancer Institute1996–1998
- Molecular Cytogenetics Of Solid TumorsNational Cancer Institute1990–1994
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
